Almassinokiani Fariba, Almasi Alireza, Akbari Peyman, Saberifard Mahboubeh
1. Associate Professor, Minimally Invasive Surgery Research Center, Iran University of Medical Sciences, Department of gynecology and obstetrics, Rasool Akram Hospital, Tehran, Iran.
2. Assistant Professor, Iran University of Medical Sciences, Firoozgar Hospital, Tehran, Iran.
Med J Islam Repub Iran. 2014 Oct 4;28:107. eCollection 2014.
To determine the role of Letrozole, an aromatase inhibitor, in the treatment of endometriotic pain.
In this prospective, randomized, controlled clinical trial in minimally invasive surgery research center, 51 women with pelvic endometriosis and endometriotic pain (dyspareunia, dysmenorrhea, pelvic pain) score of 5 or more (for at least one of these endometriotic pain), after laparoscopic diagnosis and conservative laparoscopic surgery were treated with either Letrozole plus OCP (n=25) or only OCP (n=26) for 4 months continuously.
Using VAS test, the score of dyspareunia, dysmenorrhea and pelvic pain 4 months after the laparoscopic surgery declined significantly in both groups but the difference between results of the two groups was not significant.
Both treatment modalities showed comparable effectiveness in the treatment of pains related to endometriosis and in comparison with OCP, Letrozole did not affect the outcome.
确定芳香化酶抑制剂来曲唑在治疗子宫内膜异位症疼痛中的作用。
在这个位于微创手术研究中心的前瞻性、随机、对照临床试验中，51名患有盆腔子宫内膜异位症且子宫内膜异位症疼痛（性交困难、痛经、盆腔疼痛）评分达到5分或更高（至少其中一种子宫内膜异位症疼痛）的女性，在腹腔镜诊断和保守性腹腔镜手术后，连续4个月接受来曲唑加口服避孕药（OCP）治疗（n = 25）或仅接受口服避孕药（OCP）治疗（n = 26）。
使用视觉模拟评分法（VAS）测试，腹腔镜手术后4个月，两组的性交困难、痛经和盆腔疼痛评分均显著下降，但两组结果之间的差异不显著。
两种治疗方式在治疗与子宫内膜异位症相关的疼痛方面显示出相当的疗效，与口服避孕药相比，来曲唑不影响治疗结果。
